Treatment Education
Recovery and musculoskeletal conditions
What is and isn't established about peptides discussed for recovery.
Clinical services are not available yet. GetPeptides has not launched medical visits, prescriptions or pharmacy delivery in any state. Nothing you do here enrolls you in treatment.
Educational information only — not medical advice. A consultation with a licensed clinician never guarantees a prescription, and treatment decisions are made independently between you and your clinician.
This page is editorial content written by the GetPeptides team from the publicly available regulatory sources cited below. It has not been reviewed or approved by a qualified independent clinician or pharmacist, and it is not medical advice.
FDA-approved medications
Few peptides discussed for recovery are FDA-approved for those uses. Approved treatments for musculoskeletal conditions exist and should be discussed with a clinician.
Off-label use
Off-label prescribing in this area exists but evidence is often limited to small or early studies.
Compounded medications
Compounded preparations are made under section 503A or 503B, are not FDA-approved, and have not undergone FDA premarket review for safety, effectiveness or quality.
Investigational or unapproved substances
Many peptides popularized for recovery are investigational or unapproved for human use, and some — such as BPC-157-related substances — have been flagged by the FDA for potential safety risks in compounding. Human evidence is frequently absent, and 'research use only' products are not legal to sell for treatment.
Risks and limitations
Unknown long-term safety, quality variability and drug interactions are real concerns. A licensed clinician should evaluate any treatment decision.
Sources
- FDA: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks — editorial source list 2026-10-14
- FDA: Compounding and the FDA — Questions and Answers — editorial source list 2026-10-14
- FDA: FD&C Act Provisions that Apply to Human Drug Compounding (sections 503A and 503B) — editorial source list 2026-10-14